<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568723</url>
  </required_header>
  <id_info>
    <org_study_id>11-006510</org_study_id>
    <secondary_id>U54CA163004</secondary_id>
    <nct_id>NCT01568723</nct_id>
  </id_info>
  <brief_title>Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation</brief_title>
  <acronym>BetrnetRF</acronym>
  <official_title>Stem Cells And The Origins Of Barrett's Esophagus:Identification Of Novel Biomarkers And Gene Signatures In Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine biomarkers which can predict response to ablation&#xD;
      therapy in patients with Barretts esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Project is designed to identify biologically-based and clinically-useful biomarkers of&#xD;
      tissue at risk for neoplastic progression as well as of response to ablation therapy. These&#xD;
      results will result in improved risk stratification in BE and better targeting of resources&#xD;
      for patients who are candidates for ablative therapy, while simultaneously providing key&#xD;
      information regarding the origins of Barrett's esophagus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to therapy</measure>
    <time_frame>one year post ablation</time_frame>
    <description>evaulation will be made at 3 month intervals for one year post ablation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <description>participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>response to therapy</intervention_name>
    <description>evaluate specific markers for response to therapy at specific intervals pre and post therapy</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biopsy samples, serum, plasma, buffycoat, cytology brushings&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants must have biopsy proven Barret's esophgus with evidence of specialized&#xD;
        intestinal epithelium with high grade dysplasia or early intramucosal carcinoma (mEAC) on&#xD;
        histology (confirmed by two pathologists). Patients must have a BE length ≥ 2 cm and ≤ 8&#xD;
        cm.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Barrett's esophagus with high grade dysplasia or intramucosal (early) adenocarcinoma.&#xD;
&#xD;
          -  BE length ≥ 2 cm and ≤ 8 cm.&#xD;
&#xD;
          -  Able to return every 3 months for one year after ablation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to be compliant with follow-up endoscopies&#xD;
&#xD;
          -  patients who cannot tolerate Proton Pump inhibitors&#xD;
&#xD;
          -  pre-existing esophageal strictures&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kenneth K. Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>high grade dysplasia</keyword>
  <keyword>ablation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

